5 results
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)
Primary- To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary- To evaluate the variability of the selected biomarkers between patients and within patients over time…
To evaluate the effects of IV administration of GSK3858279 in Ultraviolet B (UVB) burn inflammatory, cold pressor test and electrical pain test in the PainCart